ArticleFrontiers in physiology2025
Acute kidney injury following fatty liver ischemia-reperfusion injury: indirect protection by hepatic ferroptosis inhibition.
Article in Frontiers in physiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Preconditioning with sufentanil confers protective effects in transplantation by attenuating hepatic ischemia-reperfusion injury.World journal of transplantation · 2026Review
- The Mechanism of G Protein-Coupled Receptor Regulation of Ferroptosis in Hepatic Ischemia-Reperfusion Injury.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Background: The association between hepatic ischemia-reperfusion injury (hIRI) in steatotic livers and subsequent acute kidney injury (AKI) is well established. Ferroptosis plays a critical role in fatty liver IRI. However, whether ferroptosis also contributes to secondary AKI following hIRI remains unclear. Methods: hIRI was induced in mice fed either a high-fat, high-sucrose diet (HFD) or a normal diet (ND) to mimic the AKI commonly observed clinically after fatty liver transplantation. Kidney injury mechanisms were evaluated using histopathology, RNA sequencing, electron microscopy, and biochemical assays. Ferroptosis in the kidney was assessed by quantifying ACSL4, 4-hydroxynonenal (4-HNE), and AA-PE in homogenates and tissue sections. In parallel experiments, the lipid peroxidation inhibitor Liproxstatin-1 (Lip-1) was administered prior to hIRI to inhibit ferroptosis. Results: AKI severity was markedly increased in HFD-fed mice compared to ND controls following hIRI. Histological, transcriptomic, and cytokine analyses revealed that apoptosis and inflammation were the primary mechanisms of kidney injury after HFD + hIRI. Kidney levels of ACSL4 and 4-HNE were not significantly elevated in either group after hIRI. Lip-1 treatment significantly reduced both liver injury and AKI in HFD-fed mice but showed no protective effect in ND-fed animals. Conclusion: Apoptosis and inflammation are the prominent kidney injury mechanisms involved in AKI following fatty liver IRI. Although ferroptosis may not be directly involved in the renal injury, anti-ferroptotic intervention mitigates AKI, supporting the concept that ferroptosis-mediated liver injury may serve as the primary upstream trigger in this context.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.